Ischemic Heart Disease (IHD) is an abnormal condition of the heart that often occurs during excitement and exertion when the heart needs more blood supply. The condition occurs due to a blockage of the arteries that supply blood to the heart, which is the consequence of a buildup of plaque in the arteries. As a result of lack of sufficient blood supply, the patient may suffer from recurrent chest pain and discomfort leading to a condition called angina pectoris.
Prolonged blockage of the arteries results in lack of blood supply leading to the death of the heart tissues, which in turn causes a condition called myocardial infarction. The condition is usually asymptomatic and develops slowly. The common symptoms include chest pain and shortness of breath. A range of medications such as nitrates, statins, beta-blockers, and antiplatelet drugs, along with treatment options such as angioplasty and coronary artery bypass graft are available depending on the condition of the patient.
The growing population of individuals with IHD is the major factor that contributes towards the market growth. In addition, as per the WHO, IHD is one of the top ten causes of mortality worldwide. Moreover, the high prevalence of chronic conditions such as diabetes, hypertension, and cholesterol levels further increase the risk of suffering from cardiovascular diseases. An increase in the funding for the development of more advanced IHD drugs will help fuel the market growth. However, the availability of effective surgical treatments and catheter-based interventions may restrain the market growth.
The global ischemic heart disease drugs market is segmented on the basis of disease, drug class, and geography. Based on disease, the market is categorized into angina pectoris and myocardial infarction. Angina pectoris is further segmented into stable angina, unstable angina, and Prinzmetal's angina. Myocardial infarction is further bifurcated into STEMI and NSTEMI. Based on formulation type, the market is categorized into liposomes & nanoparticles, solution, emulsion, suspension, and ointment. Based on disease type, the market is further segmented into glaucoma, diabetic retinopathy, dry eye syndrome, macular degeneration, cataract, diabetic macular edema, and others. Based on end-users, the market is divided into hospitals, ophthalmic clinics, ambulatory surgical centers, and homecare settings. Based on geography, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as AstraZeneca, Actelion, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Baxter, Eli Lilly and Company, Novartis, Pfizer, and Sanofi have also been provided in this report.
Key Benefits
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global market.
- This report entails a detailed quantitative analysis of the current market and estimations which assists in identifying prevailing market opportunities.
- The projections in this report are made by analyzing the current trends and future market potential in terms of value.
- Competitive intelligence helps understand the competitive scenario globally
- An in-depth analysis of current research and clinical developments within the market has been provided with key market dynamic factors that help understand the behavior of the market.
Ischemic Heart Disease Drugs Market Report Highlights
| Aspects | Details |
 By Disease |
|
 By Drug Class |
|
 By Region |
|
 Key Market Players | Pfizer, Bristol-Myers Squibb,, Eli Lilly And Company,, Baxter,, AstraZeneca,, Sanofi, Bayer, Actelion,, Novartis,, Boehringer Ingelheim, |
Loading Table Of Content...
